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Introduction 
 
Osteosarcoma is the most frequent primary ma-
lignant bone tumor that primarily affects chil-
dren and adolescents with an incidence of 4-5 
per million [1]. Several histological subtypes are 
distinguishable based on the morphology of the 
tumor. The most common subtype is the con-
ventional osteosarcoma, which accounts for 
75% of the cases [2]. During daily routine, a 
broad histopathological feature is observed. 
Some of them are well known prognostic factor 
[3] (e.g., chemotherapy response, tumor size) 
and others are still unraveled. The presence of 
large tumor nuclei is described in osteosar-
coma, especially in the anaplastic subtype [4]. 
However its biological relevance is still unclear. 
There has been report that cyto- or histomor-
phometric analysis may give reliable histopa-
thological information regarding tumor behav-
iour [5,6]. In 1982 Diamond et al. first used a 
measurement of the cell nucleus for estimation 
of prognosis in prostate cancer [7]. Later on, 
several other studies were carried out to estab-
lish the role of nuclear morphometry as a prog-
nostic factor [6,8,9]. It has been shown that 
nuclear morphometry is valid and accurate in 
predicting relapse in early-stage renal cell carci-
noma [10] and prognosis in rhabdomyosarcoma 
[6]. Taking advantage of the computerized nu-
clear morphometry previously described [6,11], 
the aim of this study was to clarify the relevance 
of two nuclear parameters: large area and 
round shape. In osteosarcoma, large and round 
tumor nuclei are likely to predict patient longer 
survival.  
 
Materials and methods 
 
56 preoperative biopsies were obtained from 
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42.5 μm2 and coefficient of nuclear roundness ≥ 0.7), these two parameters together were likely to be a predictive 
factor (P = 0.05). Osteosarcoma patients with large and round tumor nuclei had a better outcome than patients with 
small and polymorphic (ovoid or spindle-shaped) nuclei. In this study, nuclear morphometry proved to be a useful tool 
to shed light on the biology of osteosarcoma showing that some morphometric parameters can be easily applied to 
help identifying patients with a good prognosis. 
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56 patients with high grade osteosarcoma of 
long bones enrolled in the Brazilian osteosar-
coma treatment group study 2000 [12], from 
january 2000 to may 2004, and treated in the 
Instituto de Oncologia Pediatrica, GRAACC/
UNIFESP (Grupo de Apoio ao Adolescente e à 
Criança com Câncer/Universidade Federal de 
São Paulo). Patient data were obtained by re-
viewing pathological reports or clinical charts. 
All the cases were obtained from the Depart-
ment of Pathology of the Universidade Federal 
de São Paulo and handled according to the ethi-
cal guidelines of that institution.  
 
All the biopsies were fixed in formalin, decalci-
fied and embedded in paraffin according to the 
standard procedures. 4 µm-thick sections 
stained with Hematoxylin and Eosin (H&E) were 
used on the nuclear morphometric analysis.  
 
Assessment of patients- and tumor-related vari-
ables 
 
The following variables were evaluated: pres-
ence or absence of metastases at diagnosis, 
tumor size (< 12 cm or ≥ 12 cm), histological 
subtype, local recurrence, histological response 
to preoperative chemotherapy (good or poor 
responders) and overall survival. The subtype 
was classified following the criteria of the World 
Health Organization (WHO) classification for 
conventional osteosarcoma [1]. Good responder 
was defined as 90% tumor necrosis or more in 
the surgical specimen after preoperative che-
motherapy, and poor responder as less than 
90% necrosis [13]. Overall survival was defined 
as the time interval between the date of enroll-
ment onto the study and death from any cause, 
including secondary malignancies, or the most 
recent follow-up contact. 
 
Nuclear morphometry 
 
Nuclear morphometry was performed semiauto-
matically on H&E-stained sections using a com-
puter connected to an Olympus BX 40 micro-
scope with a x40 magnification lens as previ-
ously described [6,11]. The nuclei were manu-
ally selected and automatically measured by 
ImageJ software (NIH Image, Bethesda, MD). 
The color threshold module was used to remove 
parts of the image that not fall within the nu-
clear color range (Figure 1). For the nuclear 
morphometric evaluation the following parame-
ters were measured: 1). Area of cell nucleus 
(μm2); 2). Coefficient of nuclear roundness 
(CNR) - it defines the degree of similarity of nu-
clear shape to the circle: if the shape of the nu-
cleus is more round, the coefficient is closer to 
1. 
 
To reduce bias, the selection of the tumor nuclei 
was carried out without knowledge of the clini-
cal or pathological report. For every sample at 
least 100 nuclei were evaluated and the mean 
of all measured nuclei was used (Table 1). As 
the histological response to chemotherapy is a 
good prognostic factor in osteosarcoma patients 
Figure 1. Computerized nuclear morphometry. A. Osteosarcoma with large tumor nuclei before image processing. 
H&E, high power. B. Example of the output after image processing. The color threshold module was used to remove 
the background which allowed a precise selection of the nuclei. Nuclear measurements were automatically per-
formed regarding area and roundness. 
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[1], the mean of the nuclear area of the good 
responder cases was used as a cut-off to define 
the following types of cell nuclei: small nuclei 
and large nuclei. Nucleus was considered round 
when the roundness coefficient was above 
0.70. 
 
Statistical analysis 
 
For all statistical tests, SPSS 16.0 software was 
used. Survival curves were plotted using the 
Kaplan–Meier procedure and multivariable 
analysis was performed by using the Multivari-
ate Cox Regression method. Correlations were 
studied by contingency tables and Pearson's chi
-square (χ2) test or one-way ANOVA. P-values 
<0.05 were considered statistically significant.  
 
Results 
 
Clinical features 
 
The ages of the patients ranged from 8 to 26 
years (mean age, 20 years) and 50% of them 
(28 of 56) were in the second decade of life. 38 
patients were male and 18 were female. In 52 
cases the lesion was located in long bones of 
the lower extremity (34 femurs, 17 tibias and 1 
fibula). Additionally, twenty-four patients (42%) 
had lung metastasis at the time of diagnosis. 
The mean follow-up time was 35.1 months 
(range, 9 to 74 months). 
 
Pathologic features 
 
Pathological data for each of the 56 patients 
are summarized in Table 2. 62.5% of the cases 
were subclassified as osteoblastic, 23.2% as 
chondroblastic, 5.4% as fibroblastic and 8.9% 
as other rare variants. The proportion of good 
responders to preoperative chemotherapy was 
46% and of poor responders was 54%. 
 
Nuclear morphometry 
 
The mean values of the nuclear morphometry 
are summarized in Table 1. No significant differ-
ence in the mean value of nuclear area between 
the osteosarcoma subtypes was observed (P = 
0.10) (Table 2).  Based on the mean of the nu-
clear area of the good responder cases, a cut-
off was used to define cases with large (≥ 42.5 
μm2) and small (< 42.5 μm2) nuclei. 42 os-
teosarcomas (75%) were classified as cases 
Table 1. Distribution of clinicopathological parameters and cross-tabulations with nuclear area and coef-
ficient of nuclear roundness (CNR) 
      Nuclear Area   Nuclear Area and CNR   
No. of 
cases 
Small 
nuclei 
Large 
nuclei 
P-value Small and 
ovoid/spindle-
shaped nuclei 
Large and 
round 
nuclei 
P-value 
Roundness coefficient                 
  round nuclei 23 13 10 .00 - - - 
  non- round nuclei 33 29 4   - -   
Necrosis grade                 
  Poor responders 40 34 6 .00 36 4 .01 
  Good responders 16 8 8   10 6   
Tumor size                 
  < 12 cm 25 17 8 .27 19 6 .28 
  ≥ 12 cm 31 25 6   27 4   
Local recurrence                 
  Yes 33 22 11 .08 26 7 .43 
  No 23 20 3   20 3   
Metastasis at diagnosis                 
  Yes 26 22 4 .12 24 2 .06 
  No 30 20 10   22 8   
Death                 
  Yes 26 17 9 .12 27 3 .09 
  No 30 25 5   19 7   
  
 
                 
Variable   
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with small nuclei and 14 (25%) as cases with 
large nuclei (Figure 2). The results are shown in 
Table 2.  
 
As nuclear polymorphism is described in os-
teosarcoma, in all the studied samples, round, 
ovoid and spindle-shaped nuclei were observed. 
The coefficient of nuclear roundness was used 
to define tumors with round (≥ 0.70) or non-
round shape (< 0.70). 10 tumors (18%) were 
classified as cases with large and round nuclei 
(mean area value ≥ 42.5 μm2 and CRN ≥ 0.7) 
and 46 (82%) as cases with small and polymor-
phic (ovoid or spindle-shaped) nuclei (median 
area value < 42.5 μm2 and CRN < 0.7). The re-
sults are shown in Table 2. 
 
Among the 56 patients analyzed, 30 were alive 
at the time of the analysis (53.6%) and 26 had 
died (46.4%). No significant difference in overall 
survival between patients with large and small 
tumor nuclei was seen (P = 0.09) (Figure 3). 
However, when cases with large and round nu-
clei were analyzed jointly, these two parameters 
together were likely to be a predictive factor (P 
= 0.05) (Figure 4). Osteosarcoma patients with 
large and round tumor nuclei had a better out-
Table 2. Mean values of nuclear morphometry in the histological subtypes of osteosarcoma 
  Area (μm2) Coefficient of nuclear roundness 
Osteoblastic (n = 35) 35.17±10.59 0.67±0.03 
Chondroblastic (n = 13) 31.47±7.86 0.67±0.03 
Fibroblastic (n = 3) 34.91±12.44 0.65±0.02 
Others (n = 5) 44.77±6.85 0.72±0.05 
 
Figure 2. Osteosarcoma can display a variety of histopathological features. A. Osteosarcoma with large and round 
tumor nuclei. H&E, high power. B. Osteosarcoma with small tumor cell nuclei. H&E, high power. 
Figure 3. Kaplan-Meier overall survival curves in all 
analysed osteosarcoma patients according to nu-
clear area of tumour cells (large nuclei: ≥ 42.5 μm2; 
small nuclei: < 42.5 μm2). No differences in outcome 
between the patients was observed. 
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come than patients with small and polymorphic 
(ovoid or spindle-shaped) nuclei (Figure 4). Mul-
tivariate Cox regression analysis showed that 
large and round tumor nuclei was not an inde-
pendent predictive factor for the overall survival 
of these patients. 
 
Discussion 
 
Computerized nuclear morphometry has been 
shown as a good and cheap tool to predict pa-
tient outcome in several tumors [6,8]. During 
daily practice, differences in nuclei size and 
shape are often observed in osteosarcoma re-
flecting its broad histopathological heterogene-
ity. Large cells, up to 100 μm in diameter, are 
described in the anaplastic subtype [14]. How-
ever the relevance of larger nuclei in osteosar-
coma is still unclear. On the other hand, small 
cell osteosarcoma has a slightly worse progno-
sis [15]. It has shown that cell size and shape 
can predict the effect of chemotherapy in os-
teosarcoma [16].  
 
In this study, large nuclei were not associated to 
the chondroblastic subtype indicating that this 
feature was present in others variants. Large 
nuclei, defined only by the nuclear area, can 
have a round-, ovoid- or spindle-shape. The co-
efficient of nuclear roundness was used to iden-
tify cases with large and round nuclei. The pres-
ence of large and round tumor nuclei in os-
teosarcoma is likely to be associated with 
longer survival. Interestingly, only large nuclei 
could not predict good outcome. In this series, 
patients with large and round nuclei responded 
better to the preoperative chemotherapy and 
had a longer survival which might indicate that 
these tumors were more drug-sensitive. The 
association between two nuclear parameters, 
large area and round shape, might reflect a sub-
set of poorly differentiated osteosarcoma with 
more anaplastic features: abundant eosino-
philic cytoplasm, minimal osteoid and cartilage 
production, multiple nucleolated nuclei with 
prominent nucleoli. In preoperative biopsy, a list 
of differential diagnosis might be considered in 
the cases with large and round cell/nuclei with 
minimal osteiod formation. This list has to in-
clude malignant lymphoma, malignant mela-
noma (metastatic), metastatic carcinoma and 
malignant fibrous histiocytoma. The immunore-
activity for osteocalcin might be useful in diag-
nosing osteosarcomas [14]. 
 
In rhabdomyosarcoma, a tumor also derived 
from mesenquimal tissue, nuclear morphometry 
has shown that the clinical outcome is better if 
the nuclei seen in biopsies are more spindle-
shaped and, in the embryonal subtype, patients 
with small nuclei had a better outcome then 
patients with large nuclei [6]. It suggests that 
the relationship between nuclear size and prog-
nosis seems to be tumor specific.  
 
Taken all the findings together, nuclear mor-
phometry proved to be a useful tool to shed 
light on the biology of osteosarcoma showing 
that some morphometric parameters can be 
easily applied to help identifying patients with a 
good prognosis. 
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